| FIELD | CODE | CELL TYPE | INDICATION | DISCOVERY | Preclinical | Phase I | Phase II | Phase III |
|---|---|---|---|---|---|---|---|---|
| Autoimmune Disease | QS-002 | Umbilical cord MSC | AS |
|
||||
| ACT-141 | CAR-iNK | SLE |
|
|||||
| ACT-151 | CAAR-iNK | AS |
|
|||||
| Neurological Disease | ACT-111 | iPS-OPC | Spinal Cord Injury |
|
||||
| ACT-121 | iPS-NPC | Cerebral Stroke |
|
|||||
| ACT-161 | Functionally enhanced iOPC* | Spinal Cord Injury |
|
|||||
| Cancer | ACT-131 | iNK | Liquid Tumor |
|
||||
| ACT-171 | CAR-iNK | NSCLC |
|
|||||
| Respiratory Disease | QS-001 | Umbilical cord MSC | ARDS |
|
||||
| QS-005 | Umbilical cord MSC | COPD |
|
|||||
| Others | QS-004 | Umbilical cord MSC | Liver cirrhosis |
|
||||
| QS-003 | Umbilical cord MSC | Burns |
|
|||||
Oncology
| Program | Indication | CAR Targert(s) | Phase |
|---|---|---|---|
| FT576 (iNK) | Multiple Myeloma | BCMA | Ph 1 |
| FT222 (iNK) | B-Cell Lymphoma | CD19, 41BB | PreClin |
| FT819 (iT) | B-Cell Malignancies | CD19 | Ph 1 |
| FT825 (iT) | Solid tumors | HER2 | Ph 1 |
| Undisclosed | Solid tumors | Undisclosed | Research |
Autoimmune Disorders
| Program | Indication | CAR Target(s) | Phase |
|---|---|---|---|
| FT819 (iT) | Systemic Lupus Erythmatosu | CD19 | Ph 1 |
| FT222 (iNK) | Undisclosed | CD19, 41BB | Preclin |
AS = Ankylosing Spondylitis SLE = Systemic Lupus Erythematosus NSCLC = Non-small Cell Lung Cancer ARDS = Acute Respiratory Distress Syndrome
COPD = Chronic Obstructive Pulmonary Disease iNK = iPS-derived Natural Killer Cells OPC = Oligodendrocyte Progenitor Cells NPC = Neural Progenitor Cells
CAAR-iNK = Chimeric Autoantibody Receptor Engineered iNK
* First in class